Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy Meeting Abstract
| Authors: | Voss, M. H.; Kuo, F.; Chen, D.; Marker, M.; Patel, P.; Redzematovic, A.; Riaz, N.; Chan, T. A.; Choueiri, T. K.; Hsieh, J.; Motzer, R. J.; Hakimi, A. A. |
| Abstract Title: | Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 242s |
| Language: | English |
| ACCESSION: | WOS:000411931702023 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.4523 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4523 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work